Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

The Aryl Hydrocarbon Receptor (AhR) Mediates the Counter-Regulatory Effects of Pelargonidins in Models of Inflammation and Metabolic Dysfunctions.

Biagioli M, Carino A, Fiorucci C, Annunziato G, Marchianò S, Bordoni M, Roselli R, Giorgio CD, Castiglione F, Ricci P, Bruno A, Faccini A, Distrutti E, Baldoni M, Costantino G, Fiorucci S.

Nutrients. 2019 Aug 7;11(8). pii: E1820. doi: 10.3390/nu11081820.

2.

Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.

Carino A, Biagioli M, Marchianò S, Fiorucci C, Zampella A, Monti MC, Scarpelli P, Ricci P, Distrutti E, Fiorucci S.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Oct;1864(10):1422-1437. doi: 10.1016/j.bbalip.2019.07.006. Epub 2019 Jul 17.

PMID:
31325638
3.

Chenodeoxycholic Acid: An Update on Its Therapeutic Applications.

Fiorucci S, Distrutti E.

Handb Exp Pharmacol. 2019;256:265-282. doi: 10.1007/164_2019_226. Review.

PMID:
31267167
4.

GPBAR1 Functions as Gatekeeper for Liver NKT Cells and provides Counterregulatory Signals in Mouse Models of Immune-Mediated Hepatitis.

Biagioli M, Carino A, Fiorucci C, Marchianò S, Di Giorgio C, Roselli R, Magro M, Distrutti E, Bereshchenko O, Scarpelli P, Zampella A, Fiorucci S.

Cell Mol Gastroenterol Hepatol. 2019;8(3):447-473. doi: 10.1016/j.jcmgh.2019.06.003. Epub 2019 Jun 18.

5.

The Pharmacology of Bile Acids and Their Receptors.

Fiorucci S, Distrutti E.

Handb Exp Pharmacol. 2019;256:3-18. doi: 10.1007/164_2019_238. Review.

PMID:
31201555
6.

Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.

Fiorucci S, Di Giorgio C, Distrutti E.

Handb Exp Pharmacol. 2019;256:283-295. doi: 10.1007/164_2019_227. Review.

PMID:
31201552
7.

Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.

Carino A, Marchianò S, Biagioli M, Fiorucci C, Zampella A, Monti MC, Morretta E, Bordoni M, Di Giorgio C, Roselli R, Ricci P, Distrutti E, Fiorucci S.

Nutrients. 2019 May 21;11(5). pii: E1132. doi: 10.3390/nu11051132.

8.

Serum Bile Acid Levels Before and After Sleeve Gastrectomy and Their Correlation with Obesity-Related Comorbidities.

De Vuono S, Ricci MA, Nulli Migliola E, Monti MC, Morretta E, Boni M, Ministrini S, Carino A, Fiorucci S, Distrutti E, Lupattelli G.

Obes Surg. 2019 Aug;29(8):2517-2526. doi: 10.1007/s11695-019-03877-6.

PMID:
31069691
9.

Divergent Effectiveness of Multispecies Probiotic Preparations on Intestinal Microbiota Structure Depends on Metabolic Properties.

Biagioli M, Capobianco D, Carino A, Marchianò S, Fiorucci C, Ricci P, Distrutti E, Fiorucci S.

Nutrients. 2019 Feb 2;11(2). pii: E325. doi: 10.3390/nu11020325.

10.

Endocrine activities and adipogenic effects of bisphenol AF and its main metabolite.

Skledar DG, Carino A, Trontelj J, Troberg J, Distrutti E, Marchianò S, Tomašič T, Zega A, Finel M, Fiorucci S, Mašič LP.

Chemosphere. 2019 Jan;215:870-880. doi: 10.1016/j.chemosphere.2018.10.129. Epub 2018 Oct 18.

PMID:
30408883
11.

Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis.

Carino A, Marchianò S, Biagioli M, Bucci M, Vellecco V, Brancaleone V, Fiorucci C, Zampella A, Monti MC, Distrutti E, Fiorucci S.

FASEB J. 2019 Feb;33(2):2809-2822. doi: 10.1096/fj.201801373RR. Epub 2018 Oct 10.

PMID:
30303744
12.

Bile Acids Activated Receptors Regulate Innate Immunity.

Fiorucci S, Biagioli M, Zampella A, Distrutti E.

Front Immunol. 2018 Aug 13;9:1853. doi: 10.3389/fimmu.2018.01853. eCollection 2018. Review.

13.

Future trends in the treatment of non-alcoholic steatohepatitis.

Fiorucci S, Biagioli M, Distrutti E.

Pharmacol Res. 2018 Aug;134:289-298. doi: 10.1016/j.phrs.2018.07.014. Epub 2018 Jul 17. Review.

PMID:
30021122
14.

Farnesoid X receptor modulators 2014-present: a patent review.

Sepe V, Distrutti E, Fiorucci S, Zampella A.

Expert Opin Ther Pat. 2018 May;28(5):351-364. doi: 10.1080/13543776.2018.1459569. Epub 2018 Apr 13. Review.

PMID:
29649907
15.

Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases.

Fiorucci S, Biagioli M, Distrutti E.

Dig Dis Sci. 2018 Sep;63(9):2168-2171. doi: 10.1007/s10620-018-5039-y. No abstract available.

PMID:
29611077
16.

Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases.

Biagioli M, Mencarelli A, Carino A, Cipriani S, Marchianò S, Fiorucci C, Donini A, Graziosi L, Baldelli F, Distrutti E, Costantino G, Fiorucci S.

Inflamm Bowel Dis. 2017 Dec 19;24(1):123-135. doi: 10.1093/ibd/izx031.

PMID:
29272492
17.

Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity.

Biagioli M, Laghi L, Carino A, Cipriani S, Distrutti E, Marchianò S, Parolin C, Scarpelli P, Vitali B, Fiorucci S.

Front Pharmacol. 2017 Jul 28;8:505. doi: 10.3389/fphar.2017.00505. eCollection 2017.

18.

Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases.

Festa C, De Marino S, Carino A, Sepe V, Marchianò S, Cipriani S, Di Leva FS, Limongelli V, Monti MC, Capolupo A, Distrutti E, Fiorucci S, Zampella A.

Front Pharmacol. 2017 Mar 30;8:162. doi: 10.3389/fphar.2017.00162. eCollection 2017.

19.

Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis.

Cipriani S, Carino A, Masullo D, Zampella A, Distrutti E, Fiorucci S.

Sci Rep. 2017 Jan 24;7:41055. doi: 10.1038/srep41055.

20.

Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators.

Fiorucci S, Zampella A, Cirino G, Bucci M, Distrutti E.

Am J Physiol Heart Circ Physiol. 2017 Jan 1;312(1):H21-H32. doi: 10.1152/ajpheart.00577.2016. Epub 2016 Oct 7. Review.

21.

New brominated flame retardants and their metabolites as activators of the pregnane X receptor.

Gramec Skledar D, Tomašič T, Carino A, Distrutti E, Fiorucci S, Peterlin Mašič L.

Toxicol Lett. 2016 Sep 30;259:116-123. doi: 10.1016/j.toxlet.2016.08.005. Epub 2016 Aug 6.

PMID:
27506419
22.

Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis.

Mencarelli A, Cipriani S, Francisci D, Santucci L, Baldelli F, Distrutti E, Fiorucci S.

Sci Rep. 2016 Aug 5;6:30802. doi: 10.1038/srep30802.

23.

Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension.

Fiorucci S, Distrutti E.

Pharmacol Res. 2016 Sep;111:749-756. doi: 10.1016/j.phrs.2016.07.040. Epub 2016 Jul 27. Review.

PMID:
27475883
24.

The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines.

Carino A, Graziosi L, D'Amore C, Cipriani S, Marchianò S, Marino E, Zampella A, Rende M, Mosci P, Distrutti E, Donini A, Fiorucci S.

Oncotarget. 2016 Sep 20;7(38):61021-61035. doi: 10.18632/oncotarget.10477.

25.

Gut microbiota role in irritable bowel syndrome: New therapeutic strategies.

Distrutti E, Monaldi L, Ricci P, Fiorucci S.

World J Gastroenterol. 2016 Feb 21;22(7):2219-41. doi: 10.3748/wjg.v22.i7.2219. Review.

26.

Investigation on bile acid receptor regulators. Discovery of cholanoic acid derivatives with dual G-protein coupled bile acid receptor 1 (GPBAR1) antagonistic and farnesoid X receptor (FXR) modulatory activity.

Sepe V, Renga B, Festa C, Finamore C, Masullo D, Carino A, Cipriani S, Distrutti E, Fiorucci S, Zampella A.

Steroids. 2016 Jan;105:59-67. doi: 10.1016/j.steroids.2015.11.003. Epub 2015 Dec 1.

PMID:
26607331
27.

Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders.

Fiorucci S, Distrutti E.

Trends Mol Med. 2015 Nov;21(11):702-714. doi: 10.1016/j.molmed.2015.09.001. Epub 2015 Oct 16. Review.

PMID:
26481828
28.

The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma.

Renga B, Francisci D, Carino A, Marchianò S, Cipriani S, Chiara Monti M, Del Sordo R, Schiaroli E, Distrutti E, Baldelli F, Fiorucci S.

Sci Rep. 2015 Oct 15;5:15403. doi: 10.1038/srep15403.

29.

Farnesoid X receptor modulators (2011 - 2014): a patent review.

Sepe V, Distrutti E, Fiorucci S, Zampella A.

Expert Opin Ther Pat. 2015;25(8):885-96. doi: 10.1517/13543776.2015.1045413. Review.

PMID:
26183029
30.

Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application.

Sepe V, Distrutti E, Limongelli V, Fiorucci S, Zampella A.

Future Med Chem. 2015;7(9):1109-35. doi: 10.4155/fmc.15.54. Review.

PMID:
26132522
31.

Cystathionine γ-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids.

Renga B, Bucci M, Cipriani S, Carino A, Monti MC, Zampella A, Gargiulo A, d'Emmanuele di Villa Bianca R, Distrutti E, Fiorucci S.

Am J Physiol Heart Circ Physiol. 2015 Jul 1;309(1):H114-26. doi: 10.1152/ajpheart.00087.2015. Epub 2015 May 1.

32.

Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa.

Distrutti E, Santucci L, Cipriani S, Renga B, Schiaroli E, Ricci P, Donini A, Fiorucci S.

J Gastroenterol. 2015 Jul;50(7):707-19. doi: 10.1007/s00535-015-1041-8. Epub 2015 Feb 24. Review.

PMID:
25708288
33.

Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP.

Distrutti E, O'Reilly JA, McDonald C, Cipriani S, Renga B, Lynch MA, Fiorucci S.

PLoS One. 2014 Sep 9;9(9):e106503. doi: 10.1371/journal.pone.0106503. eCollection 2014.

34.

Targeting FXR in cholestasis: hype or hope.

Fiorucci S, Distrutti E, Ricci P, Giuliano V, Donini A, Baldelli F.

Expert Opin Ther Targets. 2014 Dec;18(12):1449-59. doi: 10.1517/14728222.2014.956087. Epub 2014 Sep 9. Review.

PMID:
25200104
35.

Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis.

Mencarelli A, D'Amore C, Renga B, Cipriani S, Carino A, Sepe V, Perissutti E, D'Auria MV, Zampella A, Distrutti E, Fiorucci S.

Mar Drugs. 2013 Dec 24;12(1):36-53. doi: 10.3390/md12010036.

36.

In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors.

Renga B, Mencarelli A, Cipriani S, D'Amore C, Francisci D, Santucci L, Baldelli F, Distrutti E, Fiorucci S.

Eur J Pharmacol. 2014 Jan 15;723:194-201. doi: 10.1016/j.ejphar.2013.11.035. Epub 2013 Dec 4.

PMID:
24315932
37.

FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents.

Renga B, D'Amore C, Cipriani S, Mencarelli A, Carino A, Sepe V, Zampella A, Distrutti E, Fiorucci S.

Pharmacol Res. 2013 Nov;77:1-10. doi: 10.1016/j.phrs.2013.08.008. Epub 2013 Sep 1.

PMID:
24004655
38.

Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents.

Mencarelli A, Renga B, D'Amore C, Santorelli C, Graziosi L, Bruno A, Monti MC, Distrutti E, Cipriani S, Donini A, Fiorucci S.

Diabetes. 2013 Oct;62(10):3384-93. doi: 10.2337/db13-0299. Epub 2013 Jul 8.

39.

Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome.

Distrutti E, Cipriani S, Mencarelli A, Renga B, Fiorucci S.

PLoS One. 2013 May 15;8(5):e63893. doi: 10.1371/journal.pone.0063893. Print 2013.

40.

The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation.

Renga B, Mencarelli A, Cipriani S, D'Amore C, Carino A, Bruno A, Francisci D, Zampella A, Distrutti E, Fiorucci S.

PLoS One. 2013;8(1):e54472. doi: 10.1371/journal.pone.0054472. Epub 2013 Jan 25.

41.

Role of nuclear receptors in lipid dysfunction and obesity-related diseases.

Swanson HI, Wada T, Xie W, Renga B, Zampella A, Distrutti E, Fiorucci S, Kong B, Thomas AM, Guo GL, Narayanan R, Yepuru M, Dalton JT, Chiang JY.

Drug Metab Dispos. 2013 Jan;41(1):1-11. doi: 10.1124/dmd.112.048694. Epub 2012 Oct 4.

42.

VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation.

Mencarelli A, Cipriani S, Renga B, Bruno A, D'Amore C, Distrutti E, Fiorucci S.

PLoS One. 2012;7(9):e45425. doi: 10.1371/journal.pone.0045425. Epub 2012 Sep 21.

43.

Marine sponge steroids as nuclear receptor ligands.

Fiorucci S, Distrutti E, Bifulco G, D'Auria MV, Zampella A.

Trends Pharmacol Sci. 2012 Nov;33(11):591-601. doi: 10.1016/j.tips.2012.08.004. Epub 2012 Sep 21. Review.

PMID:
23000093
44.

Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice.

Cipriani S, Mencarelli A, Bruno A, Renga B, Distrutti E, Santucci L, Baldelli F, Fiorucci S.

Br J Pharmacol. 2013 Jan;168(1):225-37. doi: 10.1111/j.1476-5381.2012.02128.x.

45.

Farnesoid X receptor: from medicinal chemistry to clinical applications.

Fiorucci S, Mencarelli A, Distrutti E, Zampella A.

Future Med Chem. 2012 May;4(7):877-91. doi: 10.4155/fmc.12.41. Review.

PMID:
22571613
46.

Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition.

Renga B, Mencarelli A, D'Amore C, Cipriani S, Baldelli F, Zampella A, Distrutti E, Fiorucci S.

FASEB J. 2012 Jul;26(7):3021-31. doi: 10.1096/fj.11-195701. Epub 2012 Mar 23.

PMID:
22447981
47.

Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders.

Fiorucci S, Zampella A, Distrutti E.

Curr Top Med Chem. 2012;12(6):605-24. Review.

PMID:
22242859
48.

Molecular determinants of gastrointestinal and liver cancers: role of bile acid activated nuclear receptors.

Renga B, Mencarelli A, Cipriani S, Distrutti E.

Curr Top Med Chem. 2012;12(6):625-36. Review.

PMID:
22242858
49.

The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis.

Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A, Fiorucci S.

PLoS One. 2011;6(10):e25637. doi: 10.1371/journal.pone.0025637. Epub 2011 Oct 27. Erratum in: PLoS One. 2013;8(1). doi:10.1371/annotation/55febddb-0209-4a48-9c14-23df882126a2.

50.

FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.

Mencarelli A, Cipriani S, Renga B, D'Amore C, Palladino G, Distrutti E, Baldelli F, Fiorucci S.

Nutr Metab Cardiovasc Dis. 2013 Feb;23(2):94-101. doi: 10.1016/j.numecd.2011.06.008. Epub 2011 Sep 15.

PMID:
21924881

Supplemental Content

Loading ...
Support Center